TB R&D Weekly Update: Podcast Interview with Peter Andersen

[wpaudio url=”/blog/media/podcasts/Andersen_Peter_finished.mp3″ text=”Click here to play the Peter Anderson Podcast” dl=”0″]

Listen to Peter Andersen Podcast

Summary: Dr. Peter Andersen is Vice President of Vaccine Research and Development at Statens Serum Institut (SSI). The WGND had the opportunity to talk with Dr. Andersen on a recent article entitled “A multistage tuberculosis vaccine that confers efficient protection before and after exposure” that we covered in a previous TB R&D Weekly Update. The article is published in Nature Medicine in February 2011. In the interview, Dr. Andersen provides an overview of his present research and the article, possible integration of a vaccine that protects pre- and post- exposure into TB treatment, and the challenges for TB vaccine development.

Additional TB R&D News:

New findings on drug tolerance in TB suggest ideas for shorter cures

BC Scientists Pioneer Method to Trace TB Outbreak

Traditional drug-discovery model ripe for reform

Sterilizing Activity of Second-Line Regimens Containing TMC207 in a Murine Model of Tuberculosis

A multistage tuberculosis vaccine that confers efficient protection before and after exposure

More News
14 Aug 2019
FDA released the following press release on Wednesday, August 14th: The U.S. Food and Drug Administration today approved Pretomanid Tablets in combination with bedaquiline and linezolid for the treatment of a specific type of highly treatment-resistant tuberculosis (TB) of the lungs. “The threat of...
27 Jun 2019
-- Globe Newswire reported on June 20th -- Spero Therapeutics, Inc. , a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bacterial infections and rare diseases, today...
5 Jun 2019
**Update: The US FDA Antimicrobial Drug Advisory Committee voted in favor of the NDA 14 to 4 on June 6th, 2019** The United States Food & Drug Administration (FDA) will host the Antimicrobial Drug Advisory Committee on Thursday, June 6th to discuss the new drug application (NDA) involving new...